The initial public offer (IPO) of Amanta Healthcare, a pharmaceutical firm in the business of sterile liquid and parenteral products, shut down its subscription process on September 3, 2025, following a phenomenal response from the investment community. The IPO, with a price band set between ₹120 to ₹126 per share, received robust bidding momentum during its three-day subscription period, reflecting strong investor optimism towards the prospects of the company’s growth.
ALSO READ | 8th Pay Commission: These People Could be the Chairman and Members
Robust Subscription Figures
On Day 3, Amanta Healthcare IPO got subscribed more than 29.29 times in total, a steep increase from previous days. The retail segment witnessed a whopping subscription of 31.04 times, while the non-institutional investors (NII) portion was subscribed 63.28 times more than it. The qualified institutional buyers (QIB) portion, however, experienced relatively lower subscription with less than complete subscription.
This high demand was fueled by investors’ optimistic perception of Amanta Healthcare’s business model and sector placement in the pharmaceutical space. The grey market premium (GMP) was at approximately 8-9%, indicating listing gain hopes of a robust listing when shares list on the stock exchanges.
ALSO READ | The ‘Ceasefire’ Donald Trump Deserves the Credit For!
Details and Objectives of IPO
Amanta Healthcare’s IPO involves a new issue of 1 crore equity shares having a total size of about ₹126 crore with no offer-for-sale component. The minimum lot size for application is 119 shares and will entail a minimum investment of around ₹14,994 at the higher price band.
The IPO proceeds are to be utilised towards a number of key aims:
- Installation of a new SteriPort production line at Kheda, Gujarat
- Setting up a line for small-volume parenterals (SVP)
- General working and corporate capital uses
These additions will further strengthen the company’s manufacturing capacity and operational efficiency, thereby being likely to benefit future revenue growth.
Steps Ahead: Allotment and Listing
The allotment basis will be settled on September 4, 2025, and the shares will get listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) by September 9, 2025. Investors who have invested in the IPO can verify their allotment status from official exchange websites and registrar portals within a short while.
ALSO READ | Individual Rights vs Nat’l Security: Delhi Riots Bail Denied for Umar-Sharjeel
Market Outlook and Analyst Views
Market analysts have graded the IPO as neutral, recommending it as a suitable long-term investment, with anticipated growth in line with trends in healthcare needs and manufacturing expansion. Sustained investor interest indicates hope for the future of Amanta Healthcare in providing sterile liquid and parenteral pharmaceuticals in an expanding sector.
Summing up, the third day of IPO subscription by Amanta Healthcare witnessed robust investor appetite, high subscription levels, and favourable market sentiment, setting the stage for a healthy public listing in early September 2025.
